{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:47Z","timestamp":1792788467658,"version":"4.5.0"},"reference-count":13,"publisher":"BMJ","issue":"1","funder":[{"name":"Goldschmidt-Jacobson","award":["na"],"award-info":[{"award-number":["na"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0528-x","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T08:02:27Z","timestamp":1550736147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma"],"prefix":"10.1136","volume":"7","author":[{"given":"Beckey","family":"Trinh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guacimara Ortega","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8910-5620","authenticated-orcid":false,"given":"Heinz","family":"L\u00e4ubli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"issue":"4","key":"528_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195\u2013207.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"528_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"Supplement_4","key":"528_CR3","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"J Haanen","year":"2018","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv264\u2013iv6.","journal-title":"Ann Oncol"},{"issue":"2","key":"528_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"key":"528_CR5","doi-asserted-by":"crossref","unstructured":"Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann SM. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2019;34(1):108-17.","DOI":"10.1093\/ndt\/gfy105"},{"issue":"7","key":"528_CR6","doi-asserted-by":"publisher","first-page":"1039 e5","DOI":"10.1016\/j.ajem.2017.02.048","volume":"35","author":"MA Win","year":"2017","unstructured":"Win MA, Thein KZ, Qdaisat A, Yeung SJ. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med. 2017;35(7):1039 e5\u20137.","journal-title":"Am J Emerg Med"},{"key":"528_CR7","doi-asserted-by":"crossref","unstructured":"Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N. ImmuneCheckpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J Clin Endocrinol Metab. 2019;104(2):550-56.","DOI":"10.1210\/jc.2018-01151"},{"issue":"12","key":"528_CR8","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1210\/jc.2009-1080","volume":"94","author":"EH Kemp","year":"2009","unstructured":"Kemp EH, Gavalas NG, Krohn KJ, Brown EM, Watson PF, Weetman AP. Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2009;94(12):4749\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"528_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017;23(5):540\u20137.","journal-title":"Nat Med"},{"issue":"2","key":"528_CR10","doi-asserted-by":"publisher","first-page":"e1386362","DOI":"10.1080\/2162402X.2017.1386362","volume":"7","author":"H Laubli","year":"2018","unstructured":"Laubli H, Koelzer VH, Matter MS, Herzig P, Dolder Schlienger B, Wiese MN, et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology. 2018;7(2):e1386362.","journal-title":"Oncoimmunology"},{"issue":"18","key":"528_CR11","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"key":"528_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-017-0249-y","volume":"5","author":"H Laubli","year":"2017","unstructured":"Laubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer. 2017;5:46.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"528_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","volume":"4","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4(5):383\u20139.","journal-title":"Cancer Immunol Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0528-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:46:53Z","timestamp":1601041613000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0528-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0528-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"19 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the local ethical committee to analyze the tissue and blood samples. Written informed consent was obtained from the patients for the analysis of the samples.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A consent for publication was obtained from the patient. A copy of the written consent is available for review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.L received travel grants and consultant fees from Bristol-Myers Squibb (BMS), Roche and Merck, Sharp and Dohme (MSD).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"52"}}